Acorda Therapeutics (ACOR) Misses Q3 EPS by 15c; Reiterates AMPYRA Net Sales Guidance

October 27, 2016 7:56 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $135.61 million versus the consensus estimate of $134.01 million.

The Company is reiterating 2016 AMPYRA net sales guidance of $475-$485 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment